Clinical Trial Update: Prevalence of Kidney Injury in Patients With HCV Treated With Sofuspovir Containing DAA Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing prevalence of kidney injury in patients with hepatitis C treated with sofusbuvir-containing direct-acting antiviral therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir-containing direct-acting antiviral therapy (sofosbuvir)

Snippet

Sponsor: Cairo University | Conditions: Investigate the Renal Effect of DAAs on Egyption Patients After Completion of Treatment | Phase 4 | Status: UNKNOWN